ArticleBMC pediatrics2025
Effect of sodium citrate anticoagulant solution in continuous veno-venous hemofiltration in critically ill children.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundAnticoagulants commonly used in the continuous veno-venous hemofiltration (CVVH) include unfractionated heparin, low-molecular-weight heparin, and sodium citrate. This study investigated the clinical anticoagulation effects of sodium citrate, low-molecular-weight heparin and non-heparin anticoagulants in critically ill children during CVVH.
methodsThis was a retrospective study based on the medical records of 86 critically ill children who were admitted to the Pediatric Intensive Care Unit of our hospital and received the CVVH treatment during January 2021 to May 2023. According to coagulation test results and choice of anticoagulant, 28 cases who received normal results in the coagulation tests and treated with low-molecular-weight heparin were classified into Group a1; 36 cases who received normal results in the coagulation tests and treated with 4% sodium citrate were classified into Group a2; 8 cases who received abnormal results in the coagulation tests and treated with a non-heparin anticoagulant were classified into Group b1; and 14 cases who received abnormal results in the coagulation tests and treated with 4% sodium citrate were classified into Group b2.
resultsNo statistically significant differences were identified in the results of blood gas and electrolyte tests before and after treatment (P > 0.05). The levels of creatinine, blood urea nitrogen and lactic acid after treatment were significantly lower than those before. No statistically significant differences were identified in activated partial thromboplastin time in Group a1 and Group a2 before and after treatment. The values of prothrombin time and platelet count in Group a2 were higher than Group a1 after treatment (P < 0.05). The incidences of treatment interruption caused by coagulation in groups a2 and b2 were lower than groups a1 and b1, respectively. Better performance was found in extending treatment duration, reducing coagulation in lines and filters and reducing the risk of bleeding in Group a2 compared with a1 (P < 0.05). No statistically significant differences were identified in the incidences of hypernatrium, hypocalcemia and acidosis/alkalosis (P > 0.05).
conclusionSodium citrate is safer and more effective in anticoagulation during CVVH compared with low-molecular-weight heparin and non-heparin anticoagulants. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.